Statistics show that the incidence of prostate cancer has climbed to the second place globally, behind lung cancer. The incidence of prostate cancer in China is as high as 10.23 / 100,000 and the mortality rate is 15.56 / 100,000. In recent years, the incidence of prostate cancer has increased by more than 5%.
Previous studies have found that sterols in mushrooms, lycopene in tomatoes, and sulforaphane in broccoli can all reduce the risk of prostate cancer.
With the improvement of the quality of life and the increase of people's health awareness, more and more people have been able to reduce the intake of high-fat foods in daily diets, increase fresh fruits and vegetables, supplement vitamins, high-quality protein and whole grains, and develop Good eating habits.
In fact, in addition to diet, proper exercise can also reduce stress and maintain a relaxed state so that prostate symptoms are relieved and prostate health is maintained.
Recently, a study published in the International Journal of Epidemiology surprisingly found that active activities can reduce the risk of prostate cancer by 51%.
Coincidentally, a study published in the British International Journal of Urology pointed out that patients with advanced prostate cancer can reduce the side effects of hormone therapy through short-term exercise.
In this study, 50 patients with advanced prostate cancer who had been treated with androgen deprivation therapy (ADT) participated in a three-month aerobic and resistance training session. Compared with the control group, the cardiovascular risk and fatigue of patients after exercise were reduced.
As we all know, androgen deprivation therapy is an important method for endocrine therapy of prostate cancer, but hormone treatment of prostate cancer will also have adverse side effects, increasing men's susceptibility to cardiovascular disease.
Androgen deprivation therapy is divided into anti-androgen therapy and castration treatment according to different mechanisms and targets. GnRH agonists and antagonists are currently commonly used castration drugs.
Among the two classes of castration drugs, GnRH agonists can cause a sudden increase in testosterone, leading to delayed castration, fluctuations in testosterone, a "rebound phenomenon", and adverse effects on the cardiovascular system.
Degarelix (drug name: Feimeng) is the only GnRH antagonist recommended for the treatment of prostate cancer. The drug directly binds to the receptor and can rapidly reduce testosterone and prostate-specific antigen (PSA) to avoid surge risk.
Clinical data show that degarelix can also significantly improve the recurrence-free survival of patients with PSA and reduce the risk of cardiovascular events and death in all patients.
To reduce the risk of prostate cancer, it is recommended that male friends develop good habits in daily life and exercise appropriately; and for patients with prostate cancer, especially those with advanced prostate cancer, you can choose GnRH with less safety and side effects according to your own condition Antagonist degarelix.
Of course, regular exercise for prostate cancer patients while taking medicine is also an important measure to reduce harmful side effects and improve quality of life.